Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $49
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $48 to $49.
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $48 to $49.